Overview

Ovarian Hyperstimulation Syndrome and Cabergoline

Status:
Completed
Trial end date:
2009-03-01
Target enrollment:
0
Participant gender:
Female
Summary
Cabergoline prevents ovarian hyperstimulation syndrome in high risk patients by disrupting follicular fluid hormone microenvironmentally altering the follicular fluid levels of insulin like growth hormone -I (IGF-I), antimullerian hormone (AMH), inhibin B and hepatocyte growth factor (HGF) levels in women with PCOS and high risk of ovarian hyperstimulation syndrome (OHSS).
Phase:
N/A
Accepts Healthy Volunteers?
Accepts Healthy Volunteers
Details
Lead Sponsor:
Etlik Zubeyde Hanim Womens' Health and Teaching Hospital
Etlik Zubeyde Hanım Women's Health Care, Training and Research Hospital
Treatments:
Cabergoline
Criteria
Inclusion Criteria:

- Development of more than 14 leading follicles larger than 10 mm and serum estradiol
more than 3000 pg/ml at the end of ovulation induction with long luteal ovulation
induction protocol.

- Having the criteria of PCOS

Exclusion Criteria:

- Not having the inclusion criteria.